Differential interferon signaling in cells in liver lobules and portal areas under treatment for chronic hepatitis C by Honda Masao et al.
Differential interferon signaling in cells in
liver lobules and portal areas under treatment
for chronic hepatitis C
著者 Honda Masao, Nakamura Mikiko, Tateno Makoto,
Sakai Akito, Shimakami Tetsuro, Shirasaki
Takayoshi, Yamashita Tatsuya, Arai Kuniaki,










































































Honda et al 
 
 - 1 - 
 
Differential interferon signaling in cells in liver lobules and portal 
areas under treatment for chronic hepatitis C  
 
Running title: Gene expression under treatment for HCV 
 
Masao Honda1) 2), Mikiko Nakamura1), Makoto Tateno1), Akito Sakai1), Tetsuro Shimakami1), 
Takayoshi Shirasaki1), Tatsuya Yamashita1), Kuniaki Arai1), Taro Yamashita1), Yoshio Sakai1)  
and Shuichi Kaneko1) 
 
1) Department of Gastroenterology, Kanazawa University Graduate School of Medicine, 
Kanazawa, Japan 
2) Department of Advanced Medical Technology, Kanazawa University Graduate School of 
Health Medicine, Kanazawa, Japan 
All the authors declare that no potential competing interests exist. 
 
Abbreviations: HCV, Hepatitis C Virus; HBV, Hepatitis B Virus; miRNA, micro RNA; CH-B, 
Chronic Hepatitis B; CH-C, Chronic Hepatitis C; HCC-B, Hepatitis B-related Hepatocellular 
Carcinoma; HCC-C, Hepatitis C-related Hepatocellular Carcinoma; OCT, optimum cutting 
temperature 
 
Corresponding author:  
Shuchi kaneko, M.D., Ph.D. 
Department of Gastroenterology, Graduate School of Medicine, Kanazawa University, 
Takara-Machi 13-1, Kanazawa 920-8641, Japan  





































































Honda et al 
 
- 2 - 
Abstract  
Objective: The mechanisms of treatment resistance to interferon (IFN) and ribavirin (Rib) 
combination therapy for hepatitis C virus (HCV) infection are not known. In this study, we 
therefore explored hepatic gene expression before and during treatment. Methods: Liver 
biopsy was performed in 50 patients before therapy and repeated in 30 patients one week 
after initiating combination therapy. The cells in liver lobules (CLL) and the cells in portal 
areas (CPA) were obtained from 12 patients using laser capture microdissection (LCM). 
Results: Forty-three patients were infected with genotype 1 HCV, 20 of whom were viral 
responders (genotype 1-Rps) with treatment outcome of SVR or TR, while 23 were non-viral 
responders (genotype 1-nonRsp) with NR. Only seven patients were infected with genotype 2. 
Before treatment, the expression of IFN and Rib stimulated genes (IRSGs), 
apoptosis-associated genes, and immune reaction gene pathways were greater in genotype 
1-nonRsp than Rsp. During treatment, IRSGs were induced in genotype 1-Rsp, but not in 
nonRsp. IRSGs induction was irrelevant in genotype 2-Rsp and was mainly impaired in CLL 
but not in CPA. Pathway analysis revealed that many immune regulatory pathways were 
induced in CLL from genotype 1-Rsp, while growth factors related to angiogenesis and 
fibrogenesis were more induced in CPA from genotype 1-nonRsp. Conclusions: Impaired 
IRSGs induction in CLL reduces the sensitivity to treatment for genotype 1 HCV infection. CLL 
and CPA in the liver might be differentially involved in treatment resistance. These findings 
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Introduction 
 A human liver infected with hepatitis C virus (HCV) develops chronic hepatitis, 
cirrhosis, and in some instances, hepatocellular carcinoma (HCC). Although interferon (IFN) 
and ribavirin (Rib) combination therapy has become a popular modality for treating patients 
with chronic hepatitis C (CH-C), about 50% of patients relapse, particularly those with 
genotype 1b and high viral load [8]. The reasons for treatment failure are poorly understood. 
Many studies of IFN and Rib combination therapy for CH-C suggested that patients who 
cleared HCV viremia early during therapy tended to show favorable outcomes. On the other 
hand, patients who needed a longer period to clear HCV had poorer outcomes [4] [7] [17], and 
those who showed no response (no or minimal decrease in HCV-RNA) to IFN and Rib 
combination therapy hardly ever achieved a sustained viral response (SVR).  
To elucidate the underlying mechanism of treatment resistance, expression profiles in 
the liver [3] [6] [20] and peripheral mononuclear cells (PBMC) [10] [21] during IFN treatment 
for CH-C patients have been examined. In chronic viral hepatitis, increased numbers of 
immune regulatory cells infiltrate in liver and liver-infiltrating lymphocytes (LILs) might play 
important roles for virus eradication and are potentially linked to treatment outcome. 
Previously, we selectively isolated cells in liver lobules (CLL) and cells in the portal area (CPA) 
from biopsy specimens using laser capture microdissection (LCM) and analyzed their gene 
expression profiles [11, 19]. From these analyses, it could be speculated that the majority of 
CLL was hepatocytes and the majority of CPA was lymphocytes, although other cellular 
components such as Kupffer cells, endothelial cells, myofibroblasts, and bile duct cells 
co-existed as well. 
 In this study, to investigate further insights into the mechanisms of therapy 
resistance, we analyzed expression profiles in CLL and CPA in addition to whole liver tissues 
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Material and Methods 
Patients 
Patients with CH-C were enrolled in this study at the Graduate School of Medicine, 
Kanazawa University Hospital, Japan, between 2001 and 2007 (Table 1, Table 2). Informed 
consent was obtained from all patients and ethics approval for the study was obtained from 
the ethics committee for human genome/gene analysis research at Kanazawa University 
Graduate School of Medical Science. Thirty patients were administrated IFN-α 2b (6 MU: 
every day for 2 weeks, then three times a week for 22 weeks) (Schering-Plough K.K., Tokyo, 
Japan) and Rib (10-13 mg/kg/day) combination therapy for 24 weeks (Table 1). Twenty 
patients were administered Peg-IFN-α 2b and Rib combination therapy for 48 weeks (Table 2). 
The final outcome of the treatment was assessed at 24 weeks after cessation of combination 
therapy. In addition, ten normal liver tissues samples obtained during surgery for metastatic 
liver cancer were used as control samples.  
We defined treatment outcomes according to the decrease in viremia as follows: 
sustained viral response (SVR), clearance of HCV viremia at 24 weeks after cessation of 
therapy; transient response (TR), no detectable HCV viremia at 24 weeks but relapse during 
the follow-up period; and nonresponse (NR), HCV viremia detected at the cessation of 
therapy. We defined a patient who achieved SVR or TR as a viral responder (Rsp) and a 
patient who exhibited a NR as a non-viral responder (nonRsp). As patient 10 stopped 
treatment at 5 weeks due to an adverse side effect, we grouped this patient as Rsp based on 
the observed viral decline within 2 weeks (Table 1).  
HCV genotype was classified by the methods described by Okamoto et al. [16] 
Twenty-three patients were infected with genotype 1b and seven patients were infected with 
genotype 2 (2a; 6, 2b; 1) (Table 1, Table 2).    
Patient serum was aliquoted and stored at -20˚C until use. HCV-RNA was serially 
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TaqMan® System® ) [9] before treatment, at 48 h, 2 weeks, and 24 weeks after initiation of 
therapy and at 24 weeks after cessation of therapy.  
The grading and staging of chronic hepatitis were histologically assessed according 
to the method described by Desmet et al. (Table 1) [5].  
Preparation of liver tissue samples 
Liver biopsy samples were taken from all patients at around 1 week before treatment 
and at 1 week after starting therapy (Figure 1A). The biopsy samples were divided into three 
parts: the first part was immersed in formalin for histological assessment, the second was 
immediately frozen in liquid nitrogen tank for future RNA isolation, and the final part was 
frozen in OCT compound for LCM analysis and stored at –80°C until use. As a control, a liver 
tissue sample was surgically obtained from a patient who showed no clinical signs of hepatitis 
and was analyzed as described previously [11].  
CLL and CPA were isolated by LCM using a CRI-337 (Cell Robotics, Albuquerque, 
NM, USA) (supplement Figure 1) from the liver biopsy specimens frozen in OCT compound. 
The detailed procedure for LCM is described in the supplemental material and methods and 
was performed as previously described [11] [19].  
RNA isolation and Affymetrix gene chip analysis 
Total RNA in each liver biopsy specimen was isolated using the RNAqueous® kit 
(Ambion, Austin, TX, USA). Total RNA in the specimens frozen for LCM was isolated with a 
carrier nucleic acid (20 ng poly C) using RNAqueous®-Micro (Ambion). The quality of the 
isolated RNA was estimated after electrophoresis using an Agilent 2001 bioanalyzer (Palo 
Alto, CA, USA). Aliquots of total RNA (50 ng) isolated from the liver biopsy specimens were 
subjected to amplification with the WT-OvationTM Pico RNA Amplification System (NuGen, 
San Carlos, CA, USA) as recommended by the manufacturer. About 10 g of cDNA was 
amplified from 50 ng total RNA, and 5 g of cDNA was used for fragmentation and biotin 
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manufacturer. The biotin-labeled cDNA was suspended in 220 l of hybridization cocktail 
(NuGen), and 200 l was used for the hybridization. Half of the total RNA isolated from the 
LCM specimens was amplified twice with the TargetAmp™ 2-Round Aminoallyl-aRNA 
Amplification Kit 1.0 (EPICENTRE, Madison, WI, USA). Twenty-five micrograms of amplified 
antisense RNA was used for biotin labeling according to the manufacturer’s protocol 
Biotin-X-X-NHS (provided by EPICENTRE). The biotin-labeled aRNA was suspended in 300 
l of hybridization cocktail (Affymetrix Inc., Santa Clara, CA, USA), and 200 l was used for 
the hybridization with the Affymetrix Human 133 Plus 2.0 microarray chip containing 54,675 
probes. After stringent washing, the microarray chips were stained with 
streptavidin-phycoerythrin, and probe hybridization was determined using a GeneChip® 
Scanner 3000 (Affymetrix). Data files (CEL) were obtained with the GeneChip® Operating 
Software 1.4 (GCOS) (Affymetrix). All expression data was deposited in Gene Expression 
Omunibus (GEO; http://www.ncbi.nlm.nih.gov/geo/) (NCBI) and the accession ID is GSM 
425995. The experimental procedure is described in detail in the supplemental material and 
methods.  
Statistical and pathway analysis of gene chip data 
Statistical analysis and hierarchical clustering were performed by BRB-ArrayTools 
(http://linus.nci.nih.gov/BRB-ArrayTools.htm).  A class comparison tool based on univariate 
or paired t-tests was used to find differentially expressed genes (P<0.005). To confirm 
statistical significance, 2000 random permutations were performed, and all of the t-tests were 
re-computed for each gene. The gene set comparison was analyzed using the BioCarta and 
KEGG pathways data bases. The Fisher and Kolmogorov-Smirnov tests were performed for 
statistical evaluation (P<0.005) (BRB-ArrayTools). Functional ontology enrichment analysis 
was performed to compare the Gene Ontology (GO) process distribution of differentially 
expressed genes (P<0.05) using MetaCore™ (GeneGo, St. Joseph, MI, USA).  
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groups, standard units (Z-score) of each gene expression value were calculated as:  
      Xi-Xm 
Zi =            
       S 
where Xi is the raw expression value, Xm is the mean of the expression values in the pathway, 
and S is the standard deviation of the expression values.  
The standard units in each pathway were expressed as mean ± SEM. A P-value of 
less than 0.05 was considered significant. Multivariate analysis was performed using a logistic 
regression model with a stepwise method using JMP7 for Windows (SAS Institute, Cary, NC, 
USA). 
Quantitative Real-time detection (RTD)-PCR 
We performed quantitative real-time detection PCR (RTD)-PCR using TaqMan 
Universal Master Mix (PE Applied Biosystems, CA). Primer pairs and probes for Mx1, IFI44 
and IFITM1, and GAPDH were obtained from TaqMan assay reagents library (Applied 




Serial changes in HCV-RNA after initiation of therapy of IFN-α 2b and Rib combination 
therapy 
Serial changes in HCV-RNA were monitored at 48 h, 2 weeks, and 24 weeks after the 
initiation of therapy (Table 1). The biphasic viral decline after initiation of IFN therapy has 
been characterized [14] [15] [18]. We calculated the first phase decline by comparing viral 
load before therapy and after 48 h, and the second phase decline by comparing viral load 
after 48 h and 2 weeks (Table 1) [14][15] [18]. Both the first and second phase declines could 
be associated with treatment outcome and interestingly, viral responders (Rsp) who achieved 
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0.3-log drop of second phase decline (Log/w) (Table 1). In contrast, non-viral responders 
(nonRsp) who exhibited NR, failed to meet the criteria. The first phase decline of Rsp and 
nonRsp were 1.38 0.65 Log/24 h and 0.77 0.44 Log/24 h (p=0.005). The second phase 
decline of Rsp and nonRsp were 0.71 0.34 Log/w and 0.11 0.34 Log/w (p=0.0001) 
respectively. Therefore, the classification of Rsp or nonRsp according to the treatment 
outcome might be feasible based on the viral kinetics responding to IFN. All but one patient 
infected with genotype 2 HCV eliminated virus within 2 weeks. There were no significant 
differences in the degree of histological activity or staging, nor in the sex, age, or alanine 
aminotransferase (ALT) level among these patients (Table 1). The amount of HCV-RNA was 
significantly lower in genotype 2 patients (4.06 ± 0.32 Log IU/ml) than in genotype 1 patients 
(5.70 ± 1.10 Log IU/mL) (Table 1). 
Identification of IFN-α 2b plus Rib-induced genes in the livers of patients with chronic 
hepatitis C infection 
 To identify the genes induced in the liver by combination treatment with IFN-α 2b plus 
Rib, the gene expression profiles from samples taken around 1 week before and 1 week after 
initiation of therapy were compared. The pairwise t-test comparison showed that 798 genes 
were up-regulated and 220 genes were down-regulated significantly (P<0.005). The 100 most 
up-regulated genes according to the p-values were selected and are listed in supplement 
Table 1. Many of the interferon-stimulated genes (ISGs), such as Myxovirus (influenza virus) 
resistance 1 (MX), 2',5'-oligoadenylate synthetase (OAS), chemokine (C-C motif) ligand 8 
(CCL8), and interferon alpha-inducible protein 27 (IFI 27), were significantly induced 
(supplement Table 1). We designated these genes as IFN and Rib stimulated genes (IRSGs) 
and analyzed them further.  
Hepatic gene expression and responsiveness to IFN-α 2b and Rib combination therapy  
 To investigate the relationship between hepatic gene expression and responsiveness 
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clustering analysis using all expressed genes (n=34988) from samples taken before and 1 
week after initiation of therapy. The hierarchical clustering analysis of all patients did not form 
clear clusters, while hierarchical clustering within genotype 1 patients formed two clusters 
comprising Rsp and nonRsp (data not shown).  
 The fold changes in expression of the 100 most up-regulated IRSGs before and 
during therapy were calculated and subjected to hierarchical clustering. The hierarchical 
clustering using fold induction of IRSGs clearly differentiated Rsp, who exhibited higher 
IRSGs induction, from nonRsp, as shown in Figure 1A and supplement Table 1. Despite the 
rapid virus decline in genotype 2 patients, IRSGs induction was not so evident in these 
patients.  
Unexpectedly, the hierarchical clustering of IRSGs expression in samples taken 
before treatment showed a different pattern of gene expression (Figure 2B). The expression 
of IRSGs before treatment was significantly higher in nonRsp than in Rsp. Upon treatment, 
the expression of IRSGs was more induced in Rsp than in nonRsp (Figure 1C).  
 The findings were confirmed in patients who were administered Peg-IFN-α 2b and 
Rib combination therapy (Table 2). IRSGs expression was induced in CH-C infected livers and 
substantially up-regulated in nonRsp compared with Rsp (supplemental Figure 1). Multivariate 
logistic analysis including age, sex, fibrosis stage, activity, HCV-RNA, genotype, treatment 
regime, ALT and expression pattern of IRSGs (up or down) of 50 patients before treatment 
showed that genotype 2 (p<0.0001, Odds=4x107) and down-regulated IRSGs (p<0.0001, 
Odds=71.2) are significant variables associated with SVR. 
Gene expression analysis in cells in liver lobules (CLL) and portal area (CPA)  
To explore these findings in more detail, we examined the gene expression profiles of 
CLL and CPA that had been isolated separately from whole liver biopsy specimens of twelve 
patients, using the LCM method before and during treatment (Figure 2A). The representative 
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and Table 2-2. In CLL, liver-specific proteins and enzymes, such cytochrome P450, 
apolipoprotein, and transferrin etc., were all expressed. In CPA, cytokines, chemokines and 
lymphocyte surface markers, such as chemokine (C-X-C motif) receptor 4, interleukin-7 
receptor and CD83 antigen etc., were all expressed (supplemental Table 2-1, 2-2). The results 
confirmed our previous results that gene expression profiling obtained from the lobular area 
was mostly of hepatocyte origin and that from the portal area was mostly of liver infiltrating 
lymphocyte origin [11] [19]. 
IRSGs expression in CLL and CPA from genotype 1-Rsp and nonRsp is shown in 
Figure 2B. In genotype 1-Rsp, IRSGs expression was significantly induced in both CLL and 
CPA by the treatment (Figure 2B, 2C). On the other hand, in genotype 1-nonRsp and 
genotype 2, IRSGs induction was impaired especially in CLL, while it was nearly preserved in 
cells in CPA from three of five patients (Figure 2B, 2C). Thus, IRSGs induction in CLL should 
play an essential role in the eradication of the virus in genotype 1 CH-C patients.  
Pathway analysis of gene expression in the livers of genotype 1-Rsp, genotype 
1-nonRsp and genotype 2 
To explore which signaling pathway contributed to the impaired IRSGs induction, 
pathway comparisons between genotype 1-Rsp (n=20) and genotype 1-nonRsp (n=23) before 
treatment were performed (Table 3). Gene set comparison was analyzed based on the 
database of BioCarta and KEGG pathways. The Fisher and Kolmogorov-Smirnov tests were 
performed for statistical evaluation (P<0.005) (BRB-ArrayTools). The mean probe intensities 
of representative genes in individual pathways are shown in Table 3. In genotype 1-nonRsp, 
the signaling pathways of IFN-α, apoptosis, and many of the immune pathways, such as 
those involved in antigen presentation, and the toll-like receptor (TRL) and Jak-STAT 
signaling pathways, were generally expressed at significantly higher levels before treatment 
than genotype 1-Rsp (Table 3, Figure 3). During treatment, the immune pathways were 
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were not (Figure 3, whole liver). When the CLL and CPA were analyzed separately, significant 
induction of these pathways was observed in CLL of genotype 1-Rsp but not of genotype 
1-nonRsp and genotype 2 (Figure 3, CLL). However, similar induction patterns were observed 
in CPA among genotype 1-Rsp, genotype1-nonRsp, and genotype 2 patients (Figure 3, CPA). 
Thus, these immune pathways should be activated in CLL for the elimination of virus.  
 We then evaluated the extent of the innate immune response to treatment. The 
expression of ten innate immune response genes was strongly induced in CLL from patients 
of genotype 1-Rsp but not from genotype 1-nonRsp and genotype 2 patients, although these 
genes were similarly induced in CPA among these patients (supplemental Table 3, Figure 3).  
To examine which signaling pathways were differentially induced during treatment, 
we utilized MetaCore™. MetaCore™ is more feasible for pathway analysis using a relatively 
low number of cases, and was therefore selected to analyze the LCM samples in this study. 
The network processes involving genes for which the differential expression was statistically 
significant (P<0.05) in genotype 1 patients is shown in Figure 4. Before treatment, many of the 
immune mediated pathways, such as IFN-α, cell adhesion, IFN-γ, and TCR, were 
up-regulated in whole liver specimens from genotype 1-nonRsp compared with Rsp. Similar 
immune mediated pathways were up-regulated in CLL of genotype 1-nonRsp. In CPA, more 
of the pathways associated with cell proliferation and DNA damage were up-regulated, 
reflecting the active inflammatory process in the lymphocytes of genotype 1-nonRsp (Figure 
4-A, B, C). During treatment, more of the immune reactive pathways, such as IFN, NK cell, 
and antigen presenting, were induced in the whole liver and CLL specimens from genotype 
1-Rsp but not in nonRsp (Figure 4-D, E). In contrast, the expression of IFN-inhibitory genes 
was significantly induced in CLL from nonRsp during treatment (Table 3, Figure 4). 
Interestingly, in CPA, the IFN pathway was induced in genotype 1-Rsp and nonRsp to the 
same degree; however, signaling pathways related to angiogenesis and fibrogenesis, such as 
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1-nonRsp than from Rsp (Figure 4-F, Figure 3). Thus, differential expression of signaling 
pathways could be observed in CLL and CPA obtained from genotype 1-Rsp and nonRsp.  
 
Discussion 
IFN and Rib combination therapy has become a commonly used modality for treating 
patients with CH-C; however, the precise mechanism of treatment resistance has not yet been 
clarified. Since the development of quantitative assessment of viral kinetics during treatment, 
it has been demonstrated that patients who cleared HCV in the early period showed favorable 
outcomes, whereas patients who needed a longer time to clear HCV experienced poor 
outcomes [4] [7] [17]. Thus, early clearance of virus after initiation of treatment is one of the 
important determinants for complete eradication of HCV.   
In this study, we analyzed gene expression from liver biopsy samples obtained 
before and at one week after initiation of treatment to investigate the precise mechanisms 
involved in treatment and treatment resistance. Although global gene expression profiles in 
the liver and PBMC during the IFN treatment in a chimpanzee has been reported [12][13], the 
relationship between the expression profiles and clinical outcome could not be evaluated.  
During the preparation of this study, two reports using a similar approach have been 
published [6] [20]. For example, Feld et al. [6] analyzed gene expression in the livers of CH-C 
patients on treatment. However, the authors compared gene expression among different 
patients at initiation (n=19; 5 rapid responders, 10 slow responders, 4 naive) and during 
treatment (n=11; 6 rapid responders, 5 slow responders). Because patients were not serially 
biopsied before and during the treatment, true treatment-related gene induction could not be 
evaluated. Moreover, half of the on-treatment group was administered Rib alone for three 
days prior to liver biopsy. In the other report, Sarasin-Filipowicz et al. [20] extensively 
analyzed serial liver biopsy specimens under the treatment; however, the number of the 
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infected genotypes. Our study has extended their findings and provides further insights into 
the mechanism of IFN-resistance by analyzing gene expression in CLL and CPA separately 
for the first time. The analysis of genotype 2 HCV enabled us to understand the importance of 
the differing sensitivities to IFN between strains. 
By comparing gene expression in serial liver biopsy specimens obtained at the 
initiation and during treatment, IFN- and Rib-stimulated genes (IRSGs) in the livers of patients 
with CH-C could be identified (supplement Table 1). Our study clearly demonstrated that 
IRSGs induction correlated with the elimination of HCV in patients with genotype 1 in 
accordance with previous results [6] [20]. The patients who did not show a response to 
treatment had poor induction of IRSGs (Figure 1A). In contrast, IRSGs expression before 
treatment showed an opposite pattern of expression. IRSGs were induced in genotype 
1-nonRsp rather than in genotype 1-Rsp. This finding was first described by Chen et al. [3] 
and confirmed by others [1] [6] [20]. Asselah et al. [1] extensively analyzed 58 curated ISGs 
published previously by RTD-PCR and found that three genes (IFI27, CXCL9 and IFI-6-16) 
were predictive of treatment outcome. However, only 12 of their 58 curated genes were also 
included in the 100 most up-regulated genes we observed during treatment (supplement 
Table 1). Therefore, more valuable genes for the prediction of treatment outcome might exist 
and our gene list could be useful for further selection of predictors of treatment outcome.  
We showed that different levels of IRSGs induction before treatment was associated 
with up-regulation of different signaling pathways, such as apoptosis and inflammatory 
pathways, in genotype 1-nonRsp, although histological assessment of activities and stages 
could not differentiate the two groups of patients. During treatment, these pathways, including 
the innate immune response for IFN production, were significantly induced in genotype 1-Rsp 
but not in genotype 1-nonRsp. The results suggest that previous up-regulation of IRSGs might 
be linked to impaired induction of IRSGs and contribute to the poor response to treatment in 
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CLL, but not in CPA, and the results were confirmed by RTD-PCR (data not shown). These 
results suggest that IRSGs induction in HCV-infected hepatocytes could play an essential role 
in the eradication of the genotype 1 virus in CH-C patients.  
However, these scenarios did not apply in patients with genotype 2 HCV in this study. 
Despite the presence of active inflammation before treatment and unsatisfactory IRSGs 
induction during treatment, these patients showed rapid responses to treatment and favorable 
treatment outcomes. It could be speculated that genotype 2 HCV is far more sensitive to IFN 
than genotype 1 HCV, and small IRSGs induction might be enough to eradicate virus. Further 
studies are needed to confirm these results.  
We precisely analyzed the expression profiles in CLL and CPA obtained using the 
LCM method. Although IRSGs and other immune regulatory genes were similarly induced in 
the CPA of genotype 1-Rsp and nonRsp, more of the angiogenic- and fibrogenic-related 
genes were induced in CPA of genotype 1-nonRsp (Figure 4C, F). Therefore, growth factors 
released from CPA might be involved in poor IRSGs induction in CLL of genotype 1-nonRsp.  
 In summary, by comparing the hepatic gene expression in CH-C patients with 
different treatment outcomes, we identified a gene expression signature characteristic of IFN 
resistance. Our study is very important for two reasons: it will help in the development of new 
therapeutic strategies and many of the genes found to be up-regulated between genotype 
1-Rsp and nonRsp encode molecules secreted in serum (cytokines). Therefore, the study 
represents a logical functional approach for the development of serum markers as predictors 
of response to treatment [2]. The precise mechanisms underlying these findings should be 
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 Legends to figures 
Figure 1 
A: Hierarchical clustering of expression in genotype 1 and genotype 2 patients during 
treatment according to fold induction of IRSGs. 
B: Hierarchical clustering of expression in genotype 1 and genotype 2 patients before 
treatment. 
C: Serial changes in standardized expression values (Z-score) of IRSGs from genotype 1-Rsp, 
genotype 1-nonRsp, and genotype 2 patients before and during treatment.  
Figure 2 
A: LCM of liver biopsy samples before and during treatment. 
B: Heat map of gene expression of IRSGs in CLL and CPA before and during treatment. 
C: Serial changes in standardized expression values (Z-score) of IRSGs in CLL and CPA 
from genotype 1-Rsp, genotype 1-nonRsp, and genotype 2 patients before and during 
treatment.  
Figure 3 
Serial changes in standardized expression values (Z-score) of differentially expressed 
pathways from genotype 1-Rsp, genotype 1-nonRsp, and genotype 2 patients before and 
during treatment in whole liver, CLL, and CPA. 
Figure 4 
Functional ontology enrichment analysis of differentially expressed genes (p<0.05) using 
MetaCore™. GeneGo network process of differentially expressed genes between genotype 
1-Rsp (orange bar) and genotype 1-nonRsp (blue bar) are listed in order of decreasing 
statistical significance.  
Supplementary Figure 1 
IRSGs expression in the liver of control patients, genotype 1-Rsp and nonRsp who received 
Peg-IFN-α 2b and Rib therapy. 
Table 1. Characteristics of study patients who received IFN and ribavirin combination therapy














F A F A Log/24 h Log/week
1 M 48 1b 83 45 1 1 1 1 + 6.6 4.5 3.5 - 1.1 0.5 Rsp SVR
2 M 32 1b 192 95 1 1 1 1 - 6.4 3.9 3.2 - 1.3 0.4 Rsp SVR
3 F 50 1b 57 37 1 1 1 1 - 5.8 2.5 1.5 - 1.7 0.5 Rsp TR
4 M 36 1b 119 117 1 1 1 1 + 6.1 4.4 4.2 + 0.9 0.1 nonRsp NR
5 M 54 1b 82 69 1 1 1 1 - 6.6 5.1 3.9 + 0.8 0.6 nonRsp NR
6 M 43 1b 143 116 1 1 1 1 - 6.3 4.4 4.1 + 1.0 0.2 nonRsp NR
7 M 48 1b 33 30 1 1 1 1 + 1.5 0.0 0.0 - >0.8 - Rsp SVR
8 M 52 1b 316 374 1 2 1 1 - 4.7 5.1 3.9 + -0.2 0.6 nonRsp NR
9 M 45 1b 112 39 1 0 2 0 - 6.2 5.1 5.7 + 0.6 -0.3 nonRsp NR
10 M 48 1b 48 30 2 2 2 1 + 6.4 4.0 2.6 NA 1.2 0.8 Rsp NA
11 M 52 1b 114 80 2 2 2 1 - 6.1 3.7 3.0 - 1.2 0.4 Rsp TR
12 F 63 1b 38 30 2 1 2 1 - 5.2 4.2 4.5 + 0.5 -0.2 nonRsp NR
13 M 58 1b 90 83 2 2 2 2 + 6.9 4.9 5.6 + 1.0 -0.4 nonRsp NR
14 F 61 1b 87 43 2 1 2 1 + 6.5 3.9 3.7 + 1.3 0.1 nonRsp NR
15 F 64 1b 133 111 2 1 3 2 - 6.0 4.4 3.6 + 0.8 0.4 nonRsp NR
16 F 62 1b 251 159 3 2 3 2 - 4.8 2.7 1.5 - 1.1 0.6 Rsp SVR
17 M 54 1b 211 205 3 2 3 2 + 6.7 0.0 0.0 - >3.4 - Rsp SVR
18 F 68 1b 153 145 3 2 3 2 + 4.9 4.3 3.5 + 0.3 0.4 nonRsp NR
19 F 69 1b 64 43 3 2 3 2 - 4.4 1.5 0.0 - 1.5 0.8 Rsp SVR
20 M 49 1b 91 83 3 2 3 2 + 6.6 4.2 3.8 + 1.2 0.2 nonRsp NR
21 M 55 1b 187 196 4 1 4 2 - 5.8 5.1 5.6 + 0.4 -0.3 nonRsp NR
22 F 45 1b 113 75 4 2 3 3 - 5.7 4.2 2.7 - 0.8 0.8 Rsp TR
23 M 60 1b 86 49 4 2 3 1 - 6.3 3.5 3.5 + 1.4 0.0 nonRsp NR
24 F 51 2b 98 90 1 1 1 1 - 2.7 1.5 0.0 - 0.6 0.8 Rsp SVR
25 M 37 2a 241 211 1 0 1 0 - 4.0 1.5 0.0 - 1.3 0.8 Rsp SVR
26 F 45 2a 91 33 2 1 2 1 - 5.4 2.2 1.5 - 1.6 0.4 Rsp TR
27 M 46 2a 101 45 2 1 2 1 + 3.6 0.0 0.0 - >1.8 - Rsp SVR
28 M 54 2a 196 177 3 2 2 1 + 4.2 0.0 0.0 - >2.1 - Rsp SVR
29 F 68 2a 234 135 3 1 3 2 + 4.6 3.1 0.0 - 0.8 1.7 Rsp SVR
30 M 67 2a 155 163 4 2 4 2 - 3.9 1.5 0.0 - 1.2 0.8 Rsp SVR
NA : not applicable 1st phase decline was determined by subtracting HCV-RNA at 48 h from before therapy.
LCM: laser capture microdissection 2nd phase decline was determined by subtracting HCV-RNA at 2 wk from 48 h.
ALT: alanine aminotransferase SVR: sustained viral response
A: activity NR: nonresponse
F: fibrosis TR: transient response 
Rsp: viral responder, patients with SVR or TR
nonRsp: non-viral responder; patients with NR
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Table 2. Characteristics of patients who received Peg-IFN and ribavirin combination therapy and normal control
ALT (IU/mL)





2 wk 4 wk 24 wk Viral response Outcome
F A
1 M 57 1b 68 1 1 6.5 - - - Rsp SVR
2 F 56 1b 31 1 1 6.5 4.4 - - Rsp SVR
3 M 63 1b 50 1 1 6.1 - - - Rsp SVR
4 M 44 1b 45 1 1 6.5 3.7 - - Rsp SVR
5 F 51 1b 27 2 1 6.5 4.1 - - Rsp SVR
6 M 58 1b 72 2 1 6.2 - - - Rsp SVR
7 M 60 1b 71 2 2 6.2 3.9 - - Rsp SVR
8 F 52 1b 58 2 2 6.5 4.1 - - Rsp SVR
9 F 62 1b 60 3 2 5.9 3.8 - - Rsp SVR
10 M 55 1b 106 3 2 6.4 - - - Rsp SVR
11 M 30 1b 31 1 1 6.4 6.1 5.9 + nonRsp NR
12 F 55 1b 23 1 2 6.5 6.1 5.9 + nonRsp NR
13 M 58 1b 129 1 2 6.3 6.0 5.8 + nonRsp NR
14 M 42 1b 326 2 1 6.6 6.2 5.8 + nonRsp NR
15 F 61 1b 77 2 1 6.1 5.9 5.7 + nonRsp NR
16 F 44 1b 31 2 2 5.5 5.3 4.7 + nonRsp NR
17 M 51 1b 38 2 2 6.5 6.2 5.9 + nonRsp NR
18 F 55 1b 97 2 2 6.7 6.3 6.1 + nonRsp NR
19 M 59 1b 31 3 2 6.7 5.9 5.7 + nonRsp NR
20 F 53 1b 71 3 2 5.9 5.8 5.8 + nonRsp NR
21 F 51 - 18 0 0 - - - - - -
22 F 78 - 13 0 0 - - - - - -
23 M 75 - 20 0 0 - - - - - -
24 M 34 - 12 0 0 - - - - - -
25 M 64 - 30 0 0 - - - - - -
26 M 78 - 9 0 0 - - - - - -
27 M 53 - 19 0 0 - - - - - -
28 F 64 - 12 0 0 - - - - - -
29 F 60 - 20 0 0 - - - - - -
30 M 66 - 26 0 0 - - - - - -
SVR: sustained viral response
NR: nonresponse
Rsp: viral responder, patients with SVR or TR
nonRsp: non-viral responder; patients with NR
Before therapy
HCV-RNA (Log IU/mL)Liver histology
 
Table2
Pathway No. LS KS Representative 
of genes p-value p-value Genes Rsp (n=20) nonRsp (n=23) Normal (n=10)
Up-regulated in slow viral drop
IFN alpha signaling pathway 21 0.00001 0.00300 STAT1 1608 3117 686
IRF9 1249 1842 614
IFNAR2 1892 1988 903
Apoptotic Signaling in Response to DNA Damage 55 0.00001 0.07974 CASP3 675 870 426
CASP7 1165 1510 1264
CASP9 355 403 264
TP53 1465 1797 1028
Toll-like receptor signaling pathway 150 0.00006 0.06659 CXCL10 1922 3979 193
CXCL11 176 321 51
MYD88 1022 1372 723
TIRAP 582 722 447
Wnt signal pathway 55 0.00009 0.16058 EIF2AK2 664 1190 484
CCND1 2439 3558 1162
APC 143 186 154
PIK3R1 1570 1906 682
Antigen processing and presentation 139 0.00117 0.00091 TAP2 169 317 93
HLA-A 11005 14726 6221
HLA-B 13144 17942 6823
HLA-C 1937 3993 783
Jak-STAT signaling pathway 220 0.00180 0.13154 STAT2 716 1065 274
IL28RA 390 544 204
IL10RB 398 506 338
Down-regulated in slow viral drop
Metabolism of xenobiotics by cytochrome P450 98 0.00018 0.00082 CYP3A4 15219 10118 19256
CYP2E1 29129 24549 30929
AKR1C4 6126 4898 6671
Fatty acid metabolism 88 0.00480 0.05373 ACADL 826 687 785
ALDH2 18325 16337 21844
HSD17B4 9619 8807 10653
ACAD11 6858 6238 8279
ACOX1 6988 5862 8279
No. of genes: the number of genes comprising the pathway
Rsp: viral responder, patients with SVR or TR
nonRsp: non viral responder; patients with NR
Mean probe intensity of representative genes
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Supplemental material and methods 
RNA isolation and Affymetrix gene chip analysis 
 The liver biopsy specimens stored in liquid nitrogen were once immersed in 
RNAlater® (Ambion, Austin, TX, USA) over night and homogenized in lysis buffer by 
TissueLyser (Qiagen, Hiden, Germany). Total RNA was isolated using the RNAqueous® 
kit (Ambion, Austin, TX, USA). The quality of the isolated RNA was estimated after 
electrophoresis using an Agilent 2001 bioanalyzer (Palo Alto, CA, USA). Aliquots of total 
RNA (50 ng) isolated from the liver biopsy specimens were subjected to amplification 
with the WT-OvationTM Pico RNA Amplification System (NuGen, San Carlos, CA, USA) 
as recommended by the manufacturer (http://www.nugeninc.com/). Briefly, double 
stranded cDNA was synthesized from template RNA by using unique SPIATM DNA/RNA 
chimeric primer. The resultant cDNA with a unique DNA/RNA heterosuplex at one end 
was subjected to a linear isothermal DNA amplification under the presence of RNase H 
and DNA polymerase. RNase H degraded RNA in the DNA/RNA heterosuplex, 
generating single stranded DNA site at the 3’ end for attaching a new chimeric primer 
and start synthesizing a single stranded cDNA. This amplification cycle continues to 
generate about 10 g of cDNA from 50 ng total RNA. For the hybridization, 5 g of 
resultant cDNA was used for fragmentation and biotin labeling using the FL-OvationTM 
cDNA Biotin Module V2 (NuGen) as recommended by the manufacturer. The 
biotin-labeled cDNA was suspended in 220 l of hybridization cocktail (NuGen), and 
200l was used for the hybridization. Affymetrix Human 133 Plus 2.0 microarray chip 
(Affymetrix, Santa Clara, CA, USA) containing 54,675 gene transcripts was used for the 
analysis. Hybridization (45°C for 16hrs at 60 rpm), washing and staining (using Fluidics 
Station) were performed according to the standard protocol (Affymetrix). The probe 
array was scanned by GeneChip® Scanner 3000(Affymetrix). Hybridized data files 
(CEL) were obtained with the GeneChip® Operating Software 1.4 (GCOS) (Affymetrix).  
 For laser capture microdissection (LCM), the frozen liver biopsy specimens in 
O.C.T. compound were sliced into sections 8 m thick and immediately fixed in 
methanol for 5 min and kept on dry ice as described previously.10 Tissue samples were 
quickly stained with toluidine blue and dissected. Around 500 lymphoid cells and 
hepatocytes were excised on three slides and immersed in a denaturing solution. 
Dissection was completed within 5 min for each slide. Total RNA in LCM was isolated 
with a carrier nucleic acid (20ng poly C) using RNAqueousTM-Micro (Ambion). The 
quality of the isolated RNA was estimated after electrophoresis using an Agilent 2001 
bioanalyzer (Palo Alto, CA, USA). Usually, from 500 cells obtained, 20–40 ng total RNA 
was isolated. Half of the total RNA isolated from the LCM specimens was amplified 
twice with the TargetAmp™ 2-Round Aminoallyl-aRNA Amplification Kit 1.0 
(EPICENTRE, Madison, WI, USA). The amplification protocol was based on the 
standard antisense RNA amplification procedure using T7 RNA polymerase and 
Eberwine oligo-dT/T7 primer. Two round amplification yielded 20–40 g aRNA and 20 
μg aRNA was used for further biotin labeling using Biotin-X-X-NHS (provided by 
EPICENTRE) according to the manufacturer’s protocol. The biotin-labeled aRNA was 
suspended in 300 l of hybridization cocktail (Affymetrix Inc, Santa Clara, CA, USA), 
and 200l was used for the hybridization with the Affymetrix Human 133 Plus 2.0 
microarray chip. Hybridization, washing, staining and scanning procedures were 
performed as described. Hybridized data files (CEL) were obtained with the GeneChip® 
Operating Software 1.4 (GCOS) (Affymetrix). 
 
 Processing of gene chip data 
The intensity of each gene chip was normalized by one patient using 
GeneChip® Operating Software 1.4 (GCOS) and further processed by BRB-ArrayTools 
(http://linus.nci.nih.gov/BRB-ArrayTools.htm). The absent detection call was excluded 
and filtered data were log-transferred and normalized using median over the array 
(BRB-ArrayTools). Hierarchical clustering was performed using average linkage with 
centered correlation. A pared class comparison was performed to find the differentially 
expressed genes induced by the treatment. A gene set comparison comparison tool 
provides a list that has more genes differentially expressed and is coordinately 
regulated among predefined clinical groups than expected by chance and enables 
findings among biologically related genes to reinforce each other. The analysis was 
performed using the BioCarta and KEGG pathways data bases. The Fisher and 
Kolmogorov-Smirnov tests were performed for statistical evaluation (P<0.005) 
(BRB-ArrayTools).  
 In addition to BRB-ArrayTools, we performed the pathway analysis by using 
MetaCore™ (GeneGo, St. Joseph, MI, USA). Differentially expressed genes among 
predefined groups were extracted by using a class comparison tool (BRB-array tool) 
(P<0.05) and applied to MetaCore™ to find which category of genes were included.    
In MetaCore™, functional ontology enrichment was performed to compare the Gene 
Ontology (GO) process distribution of differentially expressed genes (P<0.05).  
 




214038_at CCL8 Chemokine (C-C motif) ligand 8 inflammatory response 1.0E-08 10.0 10.0 5.0 5.0
204439_at IFI44L Interferon-induced protein 44-like immune response 1.0E-08 5.0 10.0 2.5 3.3
229450_at IFIT3 Interferon-induced protein with tetratricopeptide repeats 3 lipid metabolic process 1.0E-08 5.0 10.0 2.5 3.3
202086_at MX1 Myxovirus (influenza virus) resistance 1 antiviral immune response 1.0E-08 5.0 10.0 2.5 3.3
242625_at RSAD2 Radical S-adenosyl methionine domain containing 2 ion transport 1.0E-08 5.0 10.0 2.5 5.0
222793_at DDX58 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 (RIG-I) innate immune response 1.0E-08 3.3 5.0 2.0 3.3
205483_s_at G1P2 Interferon, alpha-inducible protein (clone IFI-15K) ubiquitin cycle 1.0E-08 3.3 10.0 2.0 5.0
204415_at G1P3 Interferon, alpha-inducible protein (clone IFI-6-16) ubiquitin cycle 1.0E-08 3.3 5.0 2.0 2.5
219863_at HERC5 Hect domain and RLD 5 ISG15 protein ligase 1.0E-08 3.3 10.0 2.0 3.3
219352_at HERC6 Hect domain and RLD 6 ubiquitin ligases 1.0E-08 3.3 10.0 2.0 3.3
214059_at IFI44 Interferon-induced protein 44 immune response 1.0E-07 3.3 10.0 2.0 2.5
203153_at IFIT1 Interferon-induced protein with tetratricopeptide repeats 1 immune response 1.0E-08 3.3 10.0 2.5 3.3
217502_at IFIT2 Interferon-induced protein with tetratricopeptide repeats 2 negative regulation of cell proliferatio 1.0E-08 3.3 10.0 2.5 3.3
201601_x_at IFITM1 Interferon induced transmembrane protein 1 (9-27) ubiquitin cycle 4.0E-07 3.3 5.0 2.5 2.5
219684_at IFRG28 28kD interferon responsive protein RNA catabolic process 1.0E-08 3.3 5.0 2.5 3.3
204994_at MX2 Myxovirus (influenza virus) resistance 2 antiviral immune response 1.0E-08 3.3 10.0 3.3 3.3
202869_at OAS1 2',5'-oligoadenylate synthetase 1, 40/46kDa antiviral immune response 1.0E-08 3.3 10.0 2.5 2.5
204972_at OAS2 2'-5'-oligoadenylate synthetase 2, 69/71kDa antiviral immune response 1.0E-08 3.3 10.0 2.0 2.5
218400_at OAS3 2'-5'-oligoadenylate synthetase 3, 100kDa antiviral immune response 1.0E-08 3.3 10.0 2.0 2.5
228531_at SAMD9 Sterile alpha motif domain containing 9 cell differentiation 1.0E-08 3.3 5.0 2.5 2.5
219211_at USP18 Ubiquitin specific peptidase 18 ubiquitin cycle 1.0E-08 3.3 5.0 2.5 3.3
242234_at BIRC4BP XIAP associated factor-1 NF-kappaB cascade 1.2E-06 2.5 5.0 1.7 2.0
204211_x_at EIF2AK2 Eukaryotic translation initiation factor 2-alpha kinase 2 translation 1.0E-08 2.5 5.0 1.7 2.0
227609_at EPSTI1 Epithelial stromal interaction 1 (breast) expressed in breast cancer 1.0E-08 2.5 5.0 2.0 2.0
211267_at HESX1 Homeo box (expressed in ES cells) 1 development 1.0E-08 2.5 2.5 2.5 2.0
207156_at HIST1H2AG Histone 1, H2ag chromosome organization 1.0E-08 2.5 2.5 2.0 2.5
202411_at IFI27 Interferon, alpha-inducible protein 27 anti-apoptosis 3.2E-05 2.5 2.5 2.0 3.3
203596_s_at IFIT5 Interferon-induced protein with tetratricopeptide repeats 5 transcription 1.0E-08 2.5 3.3 1.7 2.5
236156_at LIPA Lipase A, lysosomal acid, cholesterol esterase protein amino acid phosphorylation 1.2E-06 2.5 5.0 2.0 3.3
209035_at MDK Midkine (neurite growth-promoting factor 2) cell proliferation 8.2E-06 2.5 2.5 2.0 2.5
217546_at MT1M metallothionein 1M metal ion binding 5.1E-06 2.5 2.0 2.0 3.3
223298_s_at NT5C3 5'-nucleotidase, cytosolic III antiviral immune response 1.0E-08 2.5 3.3 2.5 2.5
244315_at PLSCR1 Phospholipid scramblase 1 protein phosphatase 4.4E-05 2.5 5.0 1.7 2.0
228230_at PRIC285 Peroxisomal proliferator-activated receptor A interactingcomplex 285 coactivator for PPARA and PPARG 1.0E-08 2.5 5.0 1.7 2.0
226603_at SAMD9L Sterile alpha motif domain containing 9-like cell differentiation 1.0E-08 2.5 5.0 2.0 2.0
208012_x_at SP110 SP110 nuclear body protein antiviral response 1.0E-08 2.5 3.3 2.0 2.0
206271_at TLR3 Toll-like receptor 3 innate immune response 1.7E-05 2.5 2.5 2.0 2.5
34689_at TREX1 Three prime repair exonuclease 1 DNA binding 7.1E-06 2.5 3.3 2.0 1.3
208087_s_at ZBP1 Z-DNA binding protein 1 innate immune response 1.4E-05 2.5 3.3 2.5 2.0
205098_at CCR1 Chemokine (C-C motif) receptor 1 immune response 9.9E-06 2.0 2.5 2.5 1.7
208912_s_at CNP 2',3'-cyclic nucleotide 3' phosphodiesterase innate immune response 1.0E-08 2.0 2.5 2.0 2.0
233660_at EHD4 EH-domain containing 4 apoptosis 2.0E-05 2.0 3.3 2.0 1.3
224973_at FAM46A Family with sequence similarity 46, member A chemotaxis 3.0E-07 2.0 2.5 1.7 2.0
214560_at FPRL2 Formyl peptide receptor-like 2 nucleotide metabolism 6.0E-07 2.0 1.7 2.0 2.0
204187_at GMPR Guanosine monophosphate reductase development 1.0E-07 2.0 2.5 2.5 1.4
215071_s_at HIST1H2AC Histone 1, H2ac chromosome organization 6.4E-06 2.0 1.7 2.0 2.0
210387_at HIST1H2BG Histone 1, H2bg chromosome organization 4.3E-06 2.0 2.0 1.7 2.5
206332_s_at IFI16 Interferon, gamma-inducible protein 16 immune response 1.0E-08 2.0 2.5 2.0 1.7
209417_s_at IFI35 Interferon-induced protein 35 immune response 3.2E-06 2.0 3.3 1.7 2.0
33304_at ISG20 Interferon stimulated exonuclease gene 20kDa signal transduction 1.8E-06 2.0 3.3 1.7 1.7
200923_at LGALS3BP Lectin, galactoside-binding, soluble, 3 binding protein cell adhesion 1.0E-07 2.0 2.0 2.0 2.5
212713_at MFAP4 Microfibrillar-associated protein 4 metal ion binding 2.1E-05 2.0 2.5 2.5 1.7
217165_x_at MT1F Metallothionein 1F metal ion binding 6.7E-06 2.0 2.0 2.0 3.3
204745_x_at MT1G Metallothionein 1G metal ion binding 4.7E-05 2.0 1.7 1.7 3.3
206963_s_at NAT8 N-acetyltransferase 8 nucleotide metabolism 3.5E-05 2.0 2.0 2.0 2.0
225344_at NCOA7 Nuclear receptor coactivator 7 immune response 1.0E-07 2.0 2.5 1.7 2.0
210797_s_at OASL 2'-5'-oligoadenylate synthetase-like antiviral immune response 4.2E-05 2.0 3.3 1.4 2.0
218543_s_at PARP12 Poly (ADP-ribose) polymerase family, member 12 DNA repair 1.0E-08 2.0 3.3 1.7 2.0
223220_s_at PARP9 Poly (ADP-ribose) polymerase family, member 9 DNA repair 4.0E-07 2.0 2.5 1.7 2.0
209640_at PML Promyelocytic leukemia transcription 1.0E-07 2.0 2.0 2.0 2.0
225291_at PNPT1 Polyribonucleotide nucleotidyltransferase 1 positive regulation of cell proliferation 1.0E-08 2.0 3.3 1.7 2.0
235061_at PPM1K Protein phosphatase 1K (PP2C domain containing) regulation of Rab GTPase activity 1.0E-08 2.0 2.5 1.7 2.0
237105_at PRKRA Protein kinase, interferon-inducible double stranded RNA
(PKR)
antiviral immune response 3.0E-07 2.0 2.5 2.0 1.7
238743_at RIN2 Ras and Rab interactor 2 NF-kappaB cascade 1.0E-08 2.0 3.3 2.0 1.4
211456_x_at RPL35 Similar to 60S ribosomal protein L35 inflammatory response 3.1E-05 2.0 1.7 2.0 3.3





STAT1 Signal transducer and activator of transcription 1, 91kDa antiviral immune response 2.4E-06 2.0 3.3 1.4 1.4
During/Before IFN
Supplementary Table 1. One hundred genes most up-regulated by IFN and Rib combination therapy in liver of patients with chronic
hepatitis C
 
213361_at TDRD7 Tudor domain containing 7 DNA binding 1.0E-08 2.0 3.3 2.0 2.0
214329_x_at TNFSF10 Tumor necrosis factor (ligand) superfamily, member 10 inflammatory response 1.0E-07 2.0 2.5 1.7 2.0
204804_at TRIM21 Tripartite motif-containing 21 NF-kappaB cascade 1.0E-08 2.0 3.3 2.0 1.7
223830_s_at TRIM5 Tripartite motif-containing 5 DNA binding 6.0E-07 2.0 2.0 1.7 2.0
223599_at TRIM6 Tripartite motif-containing 6 DNA binding 1.0E-07 2.0 2.5 1.4 2.5
219716_at APOL6 Apolipoprotein L, 6 lipid transport 6.5E-06 1.7 2.5 1.3 1.4
201641_at BST2 Bone marrow stromal cell antigen 2 regulation of apoptosis 5.3E-05 1.7 2.0 1.4 2.0
205467_at CASP10 Caspase 10, apoptosis-related cysteine peptidase regulation of apoptosis 2.0E-07 1.7 2.0 1.7 1.3
223834_at CD274 CD274 antigen cyclic nucleotide catabolic process 3.4E-05 1.7 1.7 1.7 1.7
225415_at DTX3L Deltex 3-like (Drosophila) calcium ion binding 1.0E-08 1.7 2.5 1.4 2.0
209911_x_at HIST1H2BD Histone 1, H2bd chromosome organization 3.9E-05 1.7 1.4 2.0 2.0
209806_at HIST1H2BK Histone 1, H2bk chromosome organization 3.4E-05 1.7 1.4 1.4 2.5
232035_at HIST1H4H Histone 1, H4h chromosome organization 2.3E-05 1.7 2.0 1.4 2.0
230795_at HIST2H4 Histone 2, H4 chromosome organization 3.0E-07 1.7 1.7 1.7 2.0
212657_s_at IL1RN Interleukin 1 receptor antagonist cell adhesion 7.0E-07 1.7 2.0 1.7 1.4
208436_s_at IRF7 Interferon regulatory factor 7 innate immune response 5.0E-07 1.7 2.5 1.4 1.7
243999_at MGC19764 Likely ortholog of mouse schlafen 5 metal ion binding 3.4E-05 1.7 2.5 1.4 1.4
238025_at MLKL Mixed lineage kinase domain-like metal ion binding 5.4E-05 1.7 2.5 1.7 1.3
216336_x_at MT1K Metallothionein 1M metal ion binding 6.3E-06 1.7 1.7 1.7 2.5
203964_at NMI N-myc (and STAT) interactor nucleotide metabolism 1.0E-07 1.7 2.0 1.7 1.7
224701_at PARP14 Poly (ADP-ribose) polymerase family, member 14 DNA repair 1.8E-06 1.7 2.5 1.7 1.4
212660_at PHF15 PHD finger protein 15 RNA processing 6.8E-05 1.7 2.0 1.7 1.4
211737_x_at PTN Pleiotrophin neurite outgrowth-promoting proteins 9.5E-06 1.7 1.7 1.7 2.0
213982_s_at RABGAP1L RAB GTPase activating protein 1-like expressed in esophageal t cancer 7.4E-06 1.7 2.5 1.7 1.4
222986_s_at SCOTIN Scotin regulation of apoptosis 4.0E-06 1.7 2.0 1.4 2.0
223192_at SLC25A28 Solute carrier family 25, member 28 steroid biosynthetic process 1.0E-07 1.7 2.5 1.4 1.4
219519_s_at SN Sialoadhesin humoral immune responses 2.4E-06 1.7 2.0 1.7 1.4
226390_at STARD4 START domain containing 4, sterol regulated metabolism of cholesterol 3.8E-05 1.7 2.0 1.4 1.7
213293_s_at TRIM22 Tripartite motif-containing 22 antiviral response 1.3E-05 1.7 2.5 1.3 1.4
224806_at TRIM25 Tripartite motif-containing 25 ubiquitin cycle 3.0E-07 1.7 2.5 1.7 1.4
221044_s_at TRIM34 Tripartite motif-containing 34 ubiquitin cycle 1.0E-08 1.7 1.7 1.7 1.4
203610_s_at TRIM38 Tripartite motif-containing 38 zinc ion binding 1.0E-08 1.7 2.0 1.7 1.4
219062_s_at ZCCHC2 Zinc finger, CCHC domain containing 2 DNA binding 1.0E-08 1.7 2.5 1.7 1.7
genotype 1-Rsp:  Patients infected with genotype 1 HCV with SVR or TR
genotype 1-nonRsp:  Patients infected with genotype 1 HCV with NR
genotype 2: Patients infected with genotype 2 HCV 
 
Supplementary Table 2-1. Representative genes specifically expressed in cells in liver lobules
Probe Set Symbol Description CLL/CPA p -value
217558_at CYP2C9 Cytochrome P450, family 2, subfamily C, polypeptide 23.5 < 1e-07
207608_x_at CYP1A2 Cytochrome P450, family 1, subfamily A, polypeptide 21.5 2.00E-06
206054_at KNG1 Kininogen 1 21.2 1.00E-07
219466_s_at APOA2 Apolipoprotein A-II 18.8 1.00E-06
231398_at SLC22A7 Solute carrier family 22, member 7 18.3 1.00E-07
203400_s_at TF Transferrin 17.4 2.80E-06
1431_at CYP2E1 Cytochrome P450, family 2, subfamily E, polypeptide 17.3 9.00E-07
205216_s_at APOH Apolipoprotein H 16.9 8.00E-07
39763_at HPX Hemopexin 16.8 1.10E-06
222049_s_at RBP4 Retinol binding protein 4, plasma 16.5 3.00E-07
210049_at SERPINC1 Serpin peptidase inhibitor, clade C, member 1 16.0 6.20E-06
206305_s_at C8A Complement component 8, alpha polypeptide 14.8 1.00E-07
217238_s_at ALDOB Aldolase B, fructose-bisphosphate 14.7 3.00E-07
206754_s_at CYP2B7P1 Cytochrome P450, family 2, subfamily B, polypeptide 14.3 7.30E-06
206753_at RDH16 Retinol dehydrogenase 16 (all-trans and 13-cis) 14.2 < 1e-07
207414_s_at PCSK6 Proprotein convertase subtilisin/kexin type 6 14.0 1.00E-07
205108_s_at APOB Apolipoprotein B 14.0 6.00E-07
206119_at BHMT Betaine-homocysteine methyltransferase 13.7 1.00E-07
206386_at SERPINA7 Serpin peptidase inhibitor, clade A, member 7 13.4 1.20E-06
208470_s_at HP Haptoglobin 13.3 3.00E-07
220383_at ABCG5 ATP-binding cassette, sub-family G, member 5 13.1 5.10E-06
204988_at FGB Fibrinogen beta chain 13.0 2.39E-05
207820_at ADH1A Alcohol dehydrogenase 1A, alpha polypeptide 13.0 3.00E-07
204450_x_at APOA1 Apolipoprotein A-I 12.8 8.00E-07
205813_s_at MAT1A Methionine adenosyltransferase I, alpha 12.7 4.00E-07
206840_at AFM Afamin 12.4 9.00E-07
1554837_a_a CYP4A11 Cytochrome P450, family 4, subfamily A, polypeptide 12.4 8.00E-07
207041_at MASP2 Mannan-binding lectin serine peptidase 2 11.8 1.00E-07
209613_s_at ADH1B Alcohol dehydrogenase IB, beta polypeptide 11.6 1.00E-07
208147_s_at CYP2C8 Cytochrome P450, family 2, subfamily C, polypeptide 11.5 4.00E-07
216025_x_at CYP2C19 Cytochrome P450, family 2, subfamily C, polypeptide 11.5 < 1e-07
220224_at HAO1 Hydroxyacid oxidase (glycolate oxidase) 1 11.5 8.00E-07
207202_s_at NR1I2 Nuclear receptor subfamily 1, group I, member 2 11.4 2.60E-06
207218_at F9 Coagulation factor IX 11.4 2.00E-06
1554459_s_atCFH Complement factor H 11.1 6.00E-07
205871_at PLGLB2 Plasminogen-like B2 11.0 < 1e-07
206292_s_at SULT2A1 Sulfotransferase family, cytosolic, 2A 11.0 9.00E-07
206065_s_at DPYS Dihydropyrimidinase 10.9 2.00E-07
223781_x_at ADH4 Alcohol dehydrogenase 4 (class II), pi polypeptide 10.9 < 1e-07
211298_s_at ALB Albumin 10.8 2.57E-05
 
Supplementary Table 2-2. Representative genes specifically expressed in cells in portal areas
Probe Set Symbol Description CPA/CLL p -value
217028_at CXCR4 Chemokine (C-X-C motif) receptor 4 27.4 1.00E-07
1563674_at FCRL2 Fc receptor-like 2 22.9 < 1e-07
226218_at IL7R Interleukin 7 receptor 20.6 < 1e-07
236341_at CTLA4 Cytotoxic T-lymphocyte-associated protein 4 16.3 2.00E-06
233813_at PPP1R16B Protein phosphatase 1, regulatory (inhibitor) subunit 16B 15.7 3.20E-06
1560396_at KLHL6 Kelch-like 6 (Drosophila) 15.1 2.90E-05
230983_at BCNP1 B-cell novel protein 1 14.4 7.00E-07
213790_at ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 13.8 9.72E-05
207564_x_at OGT O-linked N-acetylglucosamine (GlcNAc) transferase 13.7 3.02E-05
1559078_at BCL11A B-cell CLL/lymphoma 11A (zinc finger protein) 13.1 2.23E-05
231093_at FCRH3 Fc receptor-like 3 13.0 3.00E-06
209771_x_at CD24 CD24 antigen 12.9 3.00E-07
230110_at MCOLN2 Mucolipin 2 12.7 1.41E-05
230894_s_at MSI2 Musashi homolog 2 (Drosophila) 12.2 6.49E-05
209480_at HLA-DQB1 Major histocompatibility complex, class II, DQ beta 1 12.1 4.60E-06
232406_at JAG1 Jagged 1 (Alagille syndrome) 11.6 1.74E-05
224406_s_at FCRL5 Fc receptor-like 5 11.1 2.00E-07
212588_at PTPRC Protein tyrosine phosphatase, receptor type, C 10.8 4.90E-06
204794_at DUSP2 Dual specificity phosphatase 2 10.4 2.57E-05
213888_s_at TRAF3IP3 TRAF3 interacting protein 3 10.3 8.00E-07
213891_s_at TCF4 Transcription factor 4 10.2 2.00E-07
213603_s_at RAC2 Ras-related C3 botulinum toxin substrate 2 9.9 < 1e-07
204563_at SELL Selectin L 9.8 5.00E-07
229686_at P2RY8 Purinergic receptor P2Y, G-protein coupled, 8 9.6 8.00E-07
236295_s_at NOD3 NOD3 protein 9.6 7.50E-06
225598_at SLC45A4 Solute carrier family 45, member 4 9.4 8.00E-07
225763_at RCSD1 RCSD domain containing 1 9.3 < 1e-07
203936_s_at MMP9 Matrix metallopeptidase 9 9.0 9.00E-07
202336_s_at PAM Peptidylglycine alpha-amidating monooxygenase 8.6 1.09E-05
201721_s_at LAPTM5 Lysosomal associated multispanning membrane protein 5 8.5 < 1e-07
204440_at CD83 CD83 antigen 8.5 6.00E-06
213193_x_at TRBV19 T cell receptor beta variable 19 8.5 < 1e-07
209828_s_at IL16 Interleukin 16 8.3 6.00E-06
205590_at RASGRP1 RAS guanyl releasing protein 1 8.3 4.48E-05
203868_s_at VCAM1 Vascular cell adhesion molecule 1 8.1 8.80E-06
202992_at C7 Complement component 7 8.0 1.13E-05
210072_at CCL19 Chemokine (C-C motif) ligand 19 8.0 5.00E-07
214247_s_at DKK3 Dickkopf homolog 3 8.0 1.40E-06
210448_s_at P2RX5 Purinergic receptor P2X, ligand-gated ion channel, 5 8.0 2.81E-05
202499_s_at SLC2A3 Solute carrier family 2, member 3 7.9 2.33E-05
 
ID Symbol Gene Name
Rsp nonRsp Rsp nonRsp Rsp nonRsp
Innate immune response genes
222793_at DDX58 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 6.2* 1.3 2.5* 1.9 5.0* 2.0*
219209_at IFIH1 Interferon induced with helicase C domain 1 (MDA5) 3.8* 1.1 5.1* 2.5* 5.0* 2.5*
231829_at KIAA1271 KIAA1271 protein (MAVS) ND ND 0.8 1.8 0.9 1.3
239876_at NFKB1 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1.3 1.2 1.0 1.9 0.8 0.7
204533_at CXCL10 Chemokine (C-X-C motif) ligand 10 3.4* 0.6 7.7* 1.5 2.0* 1.0
208436_s_at IRF7 Interferon regulatory factor 7 1.4 1.3 2.7* 2.4* 2.5* 1.4*
218520_at TBK1 TANK-binding kinase 1 2.5* 1.0 2.4 1.5 1.3 1.3
238494_at TRAF3IP1 TNF receptor-associated factor 3 interacting protein 1 1.9 0.7 0.4 0.5 1.0 1.1
205558_at TRAF6 TNF receptor-associated factor 6 2.6* 0.9 0.5 0.5* 1.0 1.1
213191_at TICAM1 Toll-like receptor adaptor molecule 1 1.2 1.0 1.0 0.6 1.3 1.1
209941_at RIPK1 Receptor (TNFRSF)-interacting serine-threonine kinase 1 1.6 0.3* 4.0 1.0 1.3* 1.4
Inhibitory genes for IFN signaling
228895_s_at ASB1 Ankyrin repeat and SOCS box-containing 1 0.7 3.2* 1.4 1.2 0.8 0.7
1563505_at DUSP16 Dual specificity phosphatase 16 0.5 3.5* 0.5* 0.4* 0.8 0.8
225452_at PPARBP PPAR binding protein 1.0 4.5* 2.2 1.2 0.8 1.1
209685_s_at PRKCB1 Protein kinase C, beta 1 0.6 3.4* 1.2 0.7 0.9 1.1
206687_s_at SHP1 Protein tyrosine phosphatase, non-receptor type 6 0.8 0.8 0.9 0.7 0.9 1.0
205128_x_at PTGS1 Prostaglandin-endoperoxide synthase 1 1.4 3.5* 1.4 0.9 0.6 1.3
211000_s_at IL6ST Interleukin 6 signal transducer (gp130, oncostatin M receptor) 1.3 3.0* 2.0 1.7 1.3 1.4*
210479_s_at RORA RAR-related orphan receptor A 0.7 3.5* 0.6 1.6 1.0 1.0
228070_at PPP2R5E Protein phosphatase 2, regulatory subunit B (B56), epsilon isoform 1.3 3.0* 1.1 1.1 1.4* 1.3*
206360_s_at SOCS3 Suppressor of cytokine signaling 3 0.8 2.3* 1.1 0.7 1.1 1.0
217864_s_at PIAS1 Protein inhibitor of activated STAT-1 1.5 1.9* 0.8 1.4 1.1 1.1
203927_at NFKBIE NFKB inhibitor epsilon 0.4 2.0* 1.3 1.5 1.0 1.1
Rsp: viral responder; patients with SVR or TR
nonRsp: non-viral responder; patients with NR
CLL: cells in liver lobles
CPA: cells in portal area
NS:not significant;  ND: not determined, *P<0.05
Supplementary Table 3. Expression of genes responsible for the innate immune response to IFN and IFN resistance in genotype 1
patients
IFN induction (During therapy/Before therapy)
CLL CPA Whole liver
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